About 1,200 million viable lymphocytes from normal but lepromin-and tuberculin-positive human beings were transfused in four patients of lepromatous and one of tuberculoid leprosy three times at monthly intervals. Three patients of lepromatous leprosy suffered from erythema nodosum, whereas the other two developed severe reaction whenever put on the smallest dose of dapsone. In one patient of lepromatous leprosy, minimal improvement or none was observed, whereas in the remaining three cases of lepromatous and one of tuberculoid leprosy, clinical, bacteriological, as well as histological improvement occurred. Two of the five patients started to tolerate the dapsone during the period of study. The present study indicates that immunotherapy might have a definite role in the management of the disese especially in cases with erythema nodosum. Lawrence factor, prepared from leucocytes of normal donors, was transfused three times into four lepromatous leprosy patients who were intolerant to anti-leprosy drugs. The donors were healthy but were tuberculin and lepromin (Mitsuda) positive. The clinical, histological, bacteriological (morphological index), and immunological assessments of the patients were performed before and 5 months after starting the immunotherapy. In two patients conversion of Mitsuda reaction occurred, but there was no appreciable improvement in the clinical, histologic, and bacteriologic status of these patients.
Leprosy is an infectious disease associated with a generalized depression of delayed allergic responses. The depression is of greater severity in patients with lepromatous leprosy and less among tuberculoid patients (1, 19) . A similar relationship between the loss of cellular immunity and the development of leprosy has also been observed in experimental animals. A disease resembling lepromatous leprosy has been produced in mice in which cell-mediated immunity has been suppressed by neonatal thymectomy and irradiation with 900 R (14) . If the mice are first transplanted with lymphoid tissue from animals with normal cellular immune state, just after thymectomy and irradiation, and are then inoculated with Mycobacterium leprae, the resulting infection is much less severe (14) . Furthermore, if, after the development of a lepromatous-type infection, the animals are made immunologically competent by the inoculation of syngeneic lymphoid cells from normal I Send reprint requests to Dr. T. N. Harris, The Children's Hospital of Philadelphia, 34th Street and Civic Center Blvd., Philadelphia, Pa. 19104. mice the disease is converted into a condition resembling borderline leprosy (15) . These observations stimulated us to study the role of homologous lymphoid transplantation obtained from normal human donors in five leprosy patients of various types. Further, it was suggested (4) that transfer factor might be adopted as a therapeutic immune reagent to convert lepromatous leprosy to the tuberculoid type. We have therefore also investigated the effect of transfusing Lawrence factor extracted from leucocytes obtained from normal donors into four lepromatous leprosy patients who were intolerant to anti-leprosy drugs.
MATERIALS AND METHODS Lymphocytic transfusion in five leprosy patients. Five patients with leprosy of different type and severity were evaluated. Classification of leprosy type was based upon clinical history, physical examination, and skin biopsy (17) . Erythema nodosum was SAHA, MITTAL, AND MAHESHWARI tuberculin units), and induction of contact type sensitivity with 2,000 gg of dinitrochlorobenzene (DNCB) followed by challenge with graded doses of the hapten (50 to 400 ug) (19) . In three patients (cases 2, 3, 5) of lepromatous leprosy, sensitivity to lepromin was also tested with 0.1 ml of Dharmendra lepromin. Then, every patient was transfused with an average of 400 million viable lymphocytes, separated from the peripheral blood of healthy but tuberculin-and lepromin-positive individuals, three times at monthly intervals. Thereafter, the patients were assessed clinically at 15-day intervals for 5 months after the first transfusion.
Each donor was tuberculin and lepromin (Mitsuda type) positive but did not exhibit any sensitivity to DNCB. Separation of lymphocytes was by the technique of Levine et al. (10) , with final suspension of cells in 100 cc of normal saline. The viability of the lymphocytes was checked by the trypan blue test. NLT test and induction of delayed hypersensitivity with tuberculin and DNCB were done by the techniques of Saha and Mittal (19) . Dharmendra lepromin, 0.1 ml, was injected on the flexor surface of the forearm, and induration was measured after 48 h (Fernadez type reaction) and 21 days (Wade-Mitsuda type reaction). An average diameter of firm induration (after 3 weeks of lepromin injection) of more than 3 mm was taken as a positive Mitsuda reaction. The skin tissue was fixed in 10% neutral formalin, embedded in paraffin, sectioned at 5 gm, and stained with hematoxylin and eosin. Special staining for the demonstration of acid-fast bacilli was by the Wade-Fite oil formaldehyde new fuchsin method (5) . Each biopsy from lepromatous leprosy patients was assessed for morphologic index expressed as percentage, granuloma index as percentage, and logarithmic index of bacilli in biopsies, viable, as recommended by Ridley (16) .
Transfusion of Lawrence transfer factor into four other lepromatous leprosy patients. Four patients of lepromatous leprosy were evaluated as described above. Classification of leprosy type was based upon clinical history, physical examination, and skin biopsy (17) . Erythema nodosum leprosum (ENL) was classified according to Waters et al. (22) . Each biopsy was assessed as described above. None of the four patients were able to tolerate dapsone at all. In each case the following skin tests were performed: lepromin test with Dharmendra antigen, tuberculin test with graded doses of old tuberculin (1, 5, and 10 tuberculin units), and DNCB contact sensitivity test with graded challenging doses of 50, 100, and 400Mgg of the hapten after sensitizing them with 2,000 ug of hapten (19) . The transfer factor was prepared from the leucocytes separated from 250 ml of blood taken from each donor. The donors were healthy, tuberculin and lepromin positive, and did not respond to 50-Mg DNCB challenge without previous sensitization. Freezing and thawing as described by Lawrence (7) was employed to extract the transfer factor from the leucocytes. Each patient received transfer factor prepared from 250 ml of blood (containing an average of 400 million viable lymphocytes) three times, at monthly intervals. Thereafter, the patients were assessed clinically at 15-day intervals for 5 months. The skin biopsies from the same sites were repeated 5 months after the first transfusion, and all the skin tests were carried out after 5 months.
To see the effect of the immunologic reconstitution therapy of the leprosy patients by lymphocytic transfusion upon humoral immunity, levels of serum immunoglobulins, complement (C3 and C4) and several autoantibodies were studied in these patients before and 5 months after the first transfusion of leucocytes. Single radial diffusion technique of Mancini et al. (11) was employed to estimate serum immunoglobulins (Ig) G, A, M, and E and serum complement (C3 and C4). Some of these patients were taken from another, similar series of eight patients who received immunotherapy by lymphocytic transfusion, and which will be reported in a subsequent communication. IgE was estimated by the use of an IgE kit (Meloy Laboratories). C-reactive protein, rheumatoid factor, and anti-streptolysin titer were determined in the sera of these patients by standard methods before and 5 months after the first transfusion. Antinucleoprotein antibody was also determined, before and after immunotherapy, using a Hyland Laboratories latex agglutination kit. In addition, tests were performed to detect leucoisoagglutinins in the sera of these patients, as described by Dacie and Lewis (2) .
RESULTS
Lymphocytic transfusion in five leprosy patients. Table 1 shows clinical, bacteriological, histological, and immunological features of the patients before lymphocytic transfusion. Patients with lepromatous leprosy suffered from ENL whereas the other two individuals developed severe reactions whenever put on even 1 mg of dapsone. All the patients were transfused with about 1,200 million viable lymphocytes in three divided doses at monthly intervals. In every patient the reaction appeared or increased in intensity after each transfusion and persisted for a period of 7 to 10 days (Table 2) . It required no therapy in all the patients except case 3. The latter needed more than the usual doses of prednisolone after every transfusion for the suppression of this phase of reaction.
No improvement was observed in the clinical status of one patient of lepromatous leprosy (case 5). His attacks of erythema nodosum decreased neither in severity nor in frequency ( Table 2 ). Definite clinical improvement was, however, observed in the other four patients (cases 1 to 4). In two of the patients (cases 3, 4) who suffered from erythema nodosum, the severity of erythema decreased progressively with every successive transfusion and both of them became free of it within the period of study. Definite bacteriological and histological improvement was observed in four of the five patients in whom clinical improvement was also found (Tables 2 and 3 ). The response was most marked in two cases, one of tuberculoid leprosy (case 1) and the other of borderline lepromatous leprosy (case 2).
Repeat immunological assessment could be done only in three patients (Table 4, Transfusion of Lawrence transfer factor into four other lepromatous leprosy patients. Table 5 shows clinical, bacteriological, histological, and immunological features of the patients before immunotherapy. None of the patients were receiving any drug at the time of the study, and none of them was able to tolerate even 1 mg of dapsone. After each intravenous transfusion, the reaction increased ( ' Tuberculin hypersensitivity was tested by graded doses of old tuberculin; DNCB contact sensitivity was tested by graded doses of DNCB. The minimum doses of old tuberculin and DNCB which could express these hypersensitivities in these patients have been given in parentheses.
of ENL in two cases, no appreciable clinical, histological, and bacteriological improvement was observed in any of the patients (Tables 6  and 7 ). However, there was considerable improvement in the status of cell-mediated immunity based upon testing with tuberculin, DNCB, and lepromin (Table 8) . Of the four recipients of transfer factor, Mitsuda reaction became positive in two cases (cases 7 and 8); this was also shown by histological examination. Sensitivity to tuberculin and DNCB could be shown with lesser doses of the respective antigens than those doses required before the transfusion.
We have also been able to follow the four patients given transfer factor until the present (8 months after the first injection). After 7.5 months, one patient (no. 7) improved clinically to a great extent. Her ENL disappeared and her appetite increased considerably. But this improvement was short lasting. After being free from lepra reaction only for 8 weeks, conditions again deteriorated to a great extent. She developed plus four ENL, high fever, and trophic ulcer on her foot. The clinical conditions of other three patients have not improved further than what was reported at the fifth month assessment. Table 9 shows that this immunotherapy caused no appreciable change in the mean serum immunoglobulins and C3 and C4 levels, except for a 43% decrease of the average IgE concentration in the sera of these patients 5 months after the beginning of lymphocytic infusion. The changes observed in other immunoglobulin levels of the sera are within experimental variation of the single radial diffusion technique. The contact sensitivity were done by challenging with graded doses of the respective antigens. The patients were sensitized with DNCB (2,000 ug) once before challenging with various doses of the hapten. They were not resensitized with DNCB after immunotherapy. The minimum doses which could express the positive tuberculin and DNCB sensitivity in these patients have been shown in the parentheses. IgEc 6,685 IU/ml 3,825 IU/ml ( <700 to 9,600 IU/ml) ( <700 to 11,000 IU/ml) a Average normal levels of IgG = 976 mg per 100 ml; IgA = 208 mg per 100 ml; IgM = 104 mg per 100 ml (Saha and Mittal, 1972) . Mean normal serum levels of C3 and C4 are 160 mg per 100 ml, and 36 mg per 100 ml, respectively (Saha and Dutta, unpublished data).
c IgE was estimated by direct method using Meloy direct IgE kit. In two cases, IgE concentration was below 700 IU/ml of serum before as well as after immunotherapy. Figures in parenthesis show the range of serum IgE levels. After lymphocytic transfusion, serum IgE levels decreased in 4, increased in 1, and remained unchanged in the remaining 2 patients. The mean level of serum IgE in normal Indians is 1,025 IU/ml; the mean level of serum IgE in leprosy patients is about five times higher than that of the normal mean value (22 The histological and bacteriological improvements observed in cases 1 and 2 may also be due to D.D.S. therapy. But this possibility is remote because these patients started to take the drug only a few weeks before the third biopsy.
The lepromin test was repeated in all the three patients at the end of the study. It showed Fernadez type of positive reaction only in one patient (case 2). Paradisi et al. (13) have also observed positive Fernadez type lepromin reaction in four of 13 patients who had previously had a negative reaction to lepromin, after injection of leucocytes from lepromin-sensitive donors into lepromatous leprosy patients. In two patients, NLT tests were repeated. In both these patients, repeat NLT tests were negative. Sensitivity tests with tuberculin and DNCB in one patient (case 3), who prior to therapy exhibited negative sensitivity to both 1,000 U of old tuberculin and 400 ,g of DNCB, showed a positive response with 10 U of old tuberculin but a negative reaction to 400 Mg of DNCB. This patient was resensitized with 2,000 Mg of DNCB and again a negative reaction was observed with a challenge dose of 400 Mg. The latter finding suggests that even after immunotherapy there had not been any appreciable improvement in the status of cell-mediated immunity although there had been some clinical and histological improvement. The observation also explains the negative lepromin and NLT tests observed in two patients after immunotherapy, and is supported by the finding that after 10 years of continuous dapsone therapy there was no reestablishment of paracortical area in the lymphnodes (Int. J. Lep., 38:443, 1970 ). Turk and Oort (21) have demonstrated that, after passive transfer of cells in an animal, the effector cells involved in the expression of a cell-mediated immune reaction are the host cells and not the passively transferred cells as had been assumed for long time. The finding that a patient (case 3) had exhibited a positive tuberculin response but could not express sensitivity to DNCB after the transfer of leucocytes from tuberculin-positive and DNCB-negative donors indicates that, in patients of leprosy, the expression component of cell-mediated immunity is intact, whereas the apparatus involved in memory formation is probably affected.
Transfusion of Lawrence transfer factor in four lepromatous leprosy patients. The role of the Lawrence transfer factor in transferring delayed hypersensitivity, and its use in the immunotherapy of immunological deficiency diseases, has been established (8, 9) . Transfusion of immunologically competent lymphocytes in an immunological deficiency disease might lead to a graft-versus-host reaction; on the other hand there is no such danger in the immunotherapy with transfer factor. But the treatment with transfusion of viable lymphocytes has a definite advantage over treatment with transfer factor in that macrophagelymphocyte interaction can take place, thus inhibiting the multiplication of the mycobacteria within the macrophages (6) . This may explain the observed clinical, histological, and bacteriological improvements with the lymphocytic transfusion in the leprosy patients, in contrast to treatment with transfer factor. In the present series of the five leprosy patients who received lymphocytic transfusion, none developed graft-versus-host reaction, which shows that the cell-mediated immunity of these patients was not too depressed to reject these grafted cells. Therefore it seems that the immune therapy of leprosy patients with viable lymphocytes is not a dangerous procedure. The Mitsuda conversion reaction which was observed in the two patients (Table 8 ) who received transfer factor can be explained, in our opinion, by the direct effect of the massive and multiple doses of transfer factor, and to the individual status of the cellular immunity.
Increased levels of IgG, A, M, and E are frequently found in cases of lepromatous leprosy and erythema nodosum leprosum (23) . The present study shows that the immunological reconstitution therapy of the leprosy patients had practically no effect on the serum immunoglobulin levels except serum IgE concentration, which was reduced by 43%. Also, the serum C3 level is reduced only by 12% after immunotherapy. This latter change is suggestive of shift of the spectrum of leprosy from lepromatous to tuberculoid end (23) and should be verified in further studies. Thus, these findings are in keeping with previous observations, which had shown no difference in the immunoglobulin levels in patients with or without ENL, although serum complement (C2 and C3) were found to be raised in patients with lepromatous leprosy. In this connection, it is worth mentioning that these patients before immunotherapy had been suffering from severe ENL which disappeared in most of them after immunotherapy (Table 2) .
It is well established that C-reactive protein, rheumatoid factor, anti-nucleoprotein antibody, and high titers of anti-streptolysin 0 are often found in the sera of leprosy patients (20) . After passive transfer of immunity into leprosy patients by lymphocyte infusion, some abnormal immunoproteins (C-reactive protein and rheumatoid factor) could not be detected which were present before such immunological intervention; it did not remove other abnormal antibodies like anti-nucleoprotein antibody, nor did it lower the anti-streptolysin levels of the sera of these patients. The exact mechanism of these findings is difficult to understand at the present moment. Appearance of leucoisoagglutinins in the sera of three patients after immunotherapy supports the previous view that such antibody may appear after multiple transfusion of leucocytes (12) .
